Search Results - "DALIANI, Danai"

Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study by Pagliaro, Lance C, Williams, Dallas L, Daliani, Danai, Williams, Michael B, Osai, William, Kincaid, Michael, Wen, Sijin, Thall, Peter F, Pettaway, Curtis A

“…Men with penile squamous cell carcinoma and regional lymph node involvement have a low probability of survival with lymphadenectomy alone. A multimodal…”
Get full text

Revisiting bleomycin from pathophysiology to safe clinical use by Froudarakis, Marios, Hatzimichael, Eleftheria, Kyriazopoulou, Lydia, Lagos, Konstantinos, Pappas, Periklis, Tzakos, Andreas G, Karavasilis, Vasilis, Daliani, Danai, Papandreou, Christos, Briasoulis, Evangelos

“…Abstract Bleomycin is a key component of curative chemotherapy regimens employed in the treatment of curable cancers, such as Hodgkin lymphoma (HL) and…”
Get full text

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer by PAPANDREOU, Christos N, DALIANI, Danai D, KIM, Jeri, ADAMS, Julian, ELLIOTT, Peter, ESSELTINE, Dixie, PETRUSICH, Alexandria, DIERINGER, Pauline, PEREZ, Cherie, LOGOTHETIS, Christopher J, NIX, Darrell, HONG YANG, MADDEN, Timothy, XUEMEI WANG, PIEN, Christine S, MILLIKAN, Randall E, TU, Shi-Ming, PAGLIARO, Lance

“…To determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5…”
Get full text

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial by CARDUCCI, Michael A, PADLEY, Robert J, SCHMITT, Jennifer L, NELSON, Joel B, BREUL, Jurgen, VOGELZANG, Nicholas J, ZONNENBERG, Bernard A, DALIANI, Danai D, SCHULMON, Claude C, NABULSI, Azmi A, HUMERICKHOUSE, Rod A, WEINBERG, Mark A

“…To evaluate the efficacy and safety of atrasentan (ABT-627), an endothelin-A receptor antagonist, in the treatment of asymptomatic, hormone-refractory…”
Get full text

Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate by PAPONDREOU, Christos N, DALIANI, Danai D, THALL, Peter F, TU, Shi-Ming, XUEMEI WANG, REYES, Adriana, TRONCOSO, Patricia, LOGOTHETIS, Christopher J

“…To determine the activity and toxicity of doxorubicin in combination with cisplatin and etoposide in patients with small-cell prostate carcinoma (SCPCa) and to…”
Get full text

Oral Toxicities in Cancer Patients, Who Receive Immunotherapy: A Case Series of 24 Patients by Nicolatou-Galitis, Ourania, Psyrri, Amanda, Tsoukalas, Nikolaos, Galitis, Evangelos, Linardou, Helena, Galiti, Dimitra, Athansiadis, Ilias, Kalapanida, Despoina, Razis, Evangelia, Katirtzoglou, Nikolaos, Kentepozidis, Nikolaos, Kosmidis, Paraskevas, Stavridi, Flora, Kyrodimos, Efthimios, Daliani, Danai, Tsironis, George, Mountzios, Giannis, Karageorgopoulou, Sofia, Gouveris, Panagiotis, Syrigos, Konstantinos

“…The oral problems of 24 cancer patients on immunotherapy between 2017–2022 and referred by their oncologists, were reported. The age range was 49–80 years, and…”
Get full text

Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience by Siefker-Radtke, Arlene O, Gee, Jason, Shen, Yu, Wen, Sijin, Daliani, Danai, Millikan, Randall E, Pisters, Louis L

“…Enteric type adenocarcinomas arising in the dome of the bladder or along the urachal ligament are uncommon. To improve our understanding of urachal carcinoma…”
Get more information

The ubiquitin‐proteasome system in cancer, a major player in DNA repair. Part 1: post‐translational regulation by Vlachostergios, Panagiotis J., Patrikidou, Anna, Daliani, Danai D., Papandreou, Christos N.

“…•  Introduction •  Proteolytic roles of UPS in DNA repair ‐  MGMT repair pathway ‐  MMR pathway ‐  BER pathway ‐  NER pathway ‐  DSB repair pathway ‐  PRR…”
Get full text

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group by BUBLEY, G. J, CARDUCCI, M, HUSSAIN, M, KAPLAN, R, MYERS, C, OH, W, PETRYLAK, D. P, REED, E, ROTH, B, SARTOR, O, SCHER, H, SIMONS, J, DAHUT, W, SINIBALDI, V, SMALL, E. J, SMITH, M. R, TRUMP, D. L, VOLLMER, R, WILDING, G, DAWSON, N, DALIANI, D, EISENBERGER, M, FIGG, W. D, FREIDLIN, B, HALABI, S, HUDES, G

“…Prostate-specific antigen (PSA) is a glycoprotein that is found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic…”
Get full text

Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma by Daliani, Danai D., Tannir, Nizar M., Papandreou, Christos N., Wang, Xuemei, Swisher, Stephen, Wood, Christopher G., Swanson, David A., Logothetis, Christopher J., Jonasch, Eric

“…OBJECTIVE To prospectively establish objective selection criteria for metastasectomy in patients with metastatic renal cell carcinoma (mRCC). PATIENTS AND…”
Get full text

Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells by Tsapakidis, Konstantinos, Vlachostergios, Panagiotis J, Voutsadakis, Ioannis A, Befani, Christina D, Patrikidou, Anna, Hatzidaki, Eleana, Daliani, Danai D, Moutzouris, George, Liakos, Panagiotis, Papandreou, Christos N

“…Objectives:  Neuropeptides are important signal initiators in advanced prostate cancer, partially acting through activation of nuclear factor kappa B. Central…”
Get full text

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan by Nelson, Joel B, Nabulsi, Azmi A, Vogelzang, Nicholas J, Breul, Jurgen, Zonnenberg, Bernard A, Daliani, Danai D, Schulman, Claude C, Carducci, Michael A

“…We examined the effects of atrasentan (endothelin-A receptor antagonist) on bone deposition and resorption markers and on bone scan index. This double-blind,…”
Get more information

Prostate Cancer Cells-Osteoblast Interaction Shifts Expression of Growth/Survival-related Genes in Prostate Cancer and Reduces Expression of Osteoprotegerin in Osteoblasts by FIZAZI, Karim, JUN YANG, KARSENTY, Gerard, NAVONE, Nora M, PELEG, Sara, SIKES, Charles R, KREIMANN, Erica L, DALIANI, Danai, OLIVE, Matilde, RAYMOND, Kevin A, JANUS, Todd J, LOGOTHETIS, Christopher J

“…Purpose: Prostate cancer specifically metastasizes to bone where it leads to bone formation. We previously reported that coculturing MDA PCa 2b prostate cancer…”
Get full text

The ubiquitin‐proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation by Vlachostergios, Panagiotis J., Patrikidou, Anna, Daliani, Danai D., Papandreou, Christos N.

“…•  Introduction •  Transcriptional modifications of DNA repair by UPS ‐  TCR pathway (NER) ‐  Protein‐DNA adducts repair ‐  BER, NER pathways ‐  MMR pathway ‐ …”
Get full text

Phase I Trial of the Angiogenesis Inhibitor TNP-470 for Progressive Androgen-independent Prostate Cancer by LOGOTHETIS, Christopher J, WU, Kenneth K, FINN, Laury D, DALIANI, Danai, FIGG, William, GHADDAR, Habib, GUTTERMAN, Jordan U

“…Clinical and laboratory observations support the view that angiogenesis is necessary for prostate cancer progression. The angiogenesis inhibitor TNP-470 has…”
Get full text

Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer by Vlachostergios, Panagiotis J, Karasavvidou, Foteini, Kakkas, Grigorios, Kapatou, Kassiani, Gioulbasanis, Ioannis, Daliani, Danai D, Moutzouris, George, Papandreou, Christos N

“…Loss of normal cell cycle control is an early event in the evolution of cancer. The expression of cyclin-dependent kinase (CDK) inhibitors p16 and p27 has been…”
Get full text

CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy by Voutsadakis, Ioannis A, Vlachostergios, Panagiotis J, Daliani, Danai D, Karasavvidou, Foteini, Kakkas, Grigorios, Moutzouris, George, Melekos, Michael D, Papandreou, Christos N

“…The cell surface endopeptidase CD10 (neutral endopeptidase) and nuclear factor-κB (NF-κB) have been independently associated with prostate cancer (PC)…”
Get more information

p53 and Cyclooxygenase-2 Expression are Directly Associated with Cyclin D1 Expression in Radical Prostatectomy Specimens of Patients with Hormone-Naïve Prostate Cancer by Vlachostergios, Panagiotis J., Karasavvidou, Foteini, Patrikidou, Anna, Voutsadakis, Ioannis A., Kakkas, Grigorios, Moutzouris, George, Zintzaras, Elias, Daliani, Danai D., Melekos, Michael D., Papandreou, Christos N.

“…Prostate cancer (PCa) is a potentially curable disease when diagnosed in early stages and subsequently treated with radical prostatectomy (RP). However, a…”
Get full text

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma by Daliani, Danai D., Papandreou, Christos N., Thall, Peter F., Wang, Xuemei, Perez, Cherie, Oliva, Rose, Pagliaro, Lance, Amato, Robert

“…BACKGROUND The highly vascular nature of renal cell carcinoma (RCC) suggests that angiogenesis inhibition may be therapeutic for patients with this disease…”
Get full text

Nonbacterial thrombotic (marantic) endocarditis in a patient with colorectal cancer by Vlachostergios, Panagiotis J, Daliani, Danai D, Dimopoulos, Vassilis, Patrikidou, Anna, Voutsadakis, Ioannis A, Papandreou, Christos N

“…Marantic endocarditis, presently termed nonbacterial thrombotic endocarditis (NBTE), is an infrequent post-mortem diagnosis in the adult population but a not…”
Get more information